Opsona Therapeutics appoints chief medical officer

Chief executive steps down for personal reasons

Opsona Therapeutics, based in Dublin, Ireland, has appointed Leon Hooftman as chief medical officer. Dr Hooftman was formerly CMO at Chroma Therapeutics (UK). Prior to this he was head of clinical development at Celltech (UK). Hooftman has also worked for Hoffmann La-Roche and Syntex.

Chief executive Dr Mark Heffernan has stepped down for personal reasons but will remain as a non-executive board member. Bernd Seizinger has been appointed executive chairman and will oversee the search for a new ceo and assume additional responsibilities for the company's operations during this period.

To further strengthen the executive management team, one of the company's founding scientists and directors, Professor Luke O'Neill will assume the additional role of chief scientific officer.

Opsona's vp of pharmaceutical development, Mary Reilly, has taken a broader role within the company as vice president of pharmaceutical development and operations.

You may also like

Research & Development

Opsona Therapeutics wins EC research grant of €5.9m

For the clinical development of lead drug candidate OPN-305
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
Subscribe now